摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7,8,9,10-tetrahydro-6H-5,6,10a-triazacyclohepta[b]naphthalen-11-one

中文名称
——
中文别名
——
英文名称
7,8,9,10-tetrahydro-6H-5,6,10a-triazacyclohepta[b]naphthalen-11-one
英文别名
2,3,4,5-tetrahydro-[1,3]diazepino[2,1-b]quinazolin-7(1H)-one;2,3,4,5-tetrahydro[1,3]diazepino[2,1-b]quinazolin-7(1H)-one;3,4,5,12-tetrahydro-2H-[1,3]diazepino[2,1-b]quinazolin-7-one
7,8,9,10-tetrahydro-6H-5,6,10a-triazacyclohepta[b]naphthalen-11-one化学式
CAS
——
化学式
C12H13N3O
mdl
MFCD00841028
分子量
215.255
InChiKey
VXLQEGSDBDDJQH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    16
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    44.7
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    7,8,9,10-tetrahydro-6H-5,6,10a-triazacyclohepta[b]naphthalen-11-one硫酸二甲酯 在 potassium hydroxide 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 1.0h, 以70%的产率得到1-methyl-2,3,4,5-tetrahydro[1,3]diazepino[2,1-b]quinazolin-7-one
    参考文献:
    名称:
    Tautomerism of quinazolin-4-ones with 2,3-annulated hydrogenated 1,3-diazaheterocycles. Synchronous and asynchronous double proton transfer in cyclic hydrogen-bonded associates
    摘要:
    量子化学方法和 1H NMR 光谱显示,在原向同分异构喹唑啉-4-酮系列中,氢化的 1,3-二氮杂环在第 2 位和第 3 位环化,即咪唑、嘧啶或 [1,3]diazepine(分别为化合物 1-3),无论这些循环的性质如何,1H-同分异构形式在气相和溶液中都占主导地位。三环 1-3 的同分异构反应是通过分子间机理进行的,中间产物是这些化合物的氢键环二聚体或它们与质子供体溶剂的环溶剂化物。反应的关键步骤是联合体内部协同的双质子转移,它可以以近乎同步和异步的模式进行。特别是,喹唑啉酮环二聚体 1-3 中的双质子转移是异步的,并以形成溶胶稳定的极性转变态的方式进行,这种转变态的结构与非一致双质子转移的离子中间体相似。
    DOI:
    10.1007/s11172-009-0111-6
  • 作为产物:
    描述:
    N-(4-azidobutyl)-N-cyanobenzamide 在 偶氮二异丁腈三正丁基氢锡 作用下, 以 为溶剂, 反应 7.5h, 以24%的产率得到7,8,9,10-tetrahydro-6H-5,6,10a-triazacyclohepta[b]naphthalen-11-one
    参考文献:
    名称:
    由N-酰基氰胺自由基合成胍基
    摘要:
    中心阶段:将氮中心自由基添加到氰胺化合物中,是芳香族多环胍衍生物的第一个自由基合成(参见方案)。底物的模块化组装使得支架的分子复杂性迅速增加,这些支架在药物化学中具有潜在的应用。
    DOI:
    10.1002/anie.200907237
点击查看最新优质反应信息

文献信息

  • Synthesis of novel 2,3-substituted quinazolin-4-ones by condensation of alkyl or aromatic diamines with 5-(N-arylimino)-4-chloro-5H-1,2,3-dithiazoles
    作者:Maria de Fatima Pereira、Valérie Thiéry、Thierry Besson
    DOI:10.1016/j.tet.2006.11.028
    日期:2007.1
    N-(4-chloro-5H-1,2,3-dithiazol-5-ylidene)-anthranilates to afford quinazolines, which are very interesting starting materials for the access to novel 2,3-condensed quinazolin-4-ones. On the other side, aromatic amines allow the synthesis of polycyclic molecules, which are structurally close to the model natural products (e.g., rutaecarpine, luotonine, tryptanthrine and vasicinone).
    本文描述的工作是Appel盐在新型杂环概念中的效用的另一个示例。我们证实,伯烷基二胺可能容易与N-(4-氯-5 H -1,2,3-二噻唑-5-亚甲基)-邻氨基苯甲酸甲酯反应生成喹唑啉,这是获得新颖化合物的非常有趣的起始原料2,3-缩合的喹唑啉-4-酮。另一方面,芳族胺允许合成多环分子,该多环分子在结构上接近模型天然产物(例如,芸香芸香碱,色氨酸,色氨酸和血管紧张素)。
  • Radical Synthesis of Guanidines from<i>N</i>-Acyl Cyanamides
    作者:Marie-Hélène Larraufie、Cyril Ollivier、Louis Fensterbank、Max Malacria、Emmanuel Lacôte
    DOI:10.1002/anie.200907237
    日期:2010.3.15
    Center stage: Additions of nitrogen‐centered radicals to cyanamide compounds provided the first radical synthesis of aromatic polycyclic guanidine derivatives (see scheme). Modular assembly of the substrates allows for a rapid increase of the molecular complexity of scaffolds, which have potential applications for medicinal chemistry.
    中心阶段:将氮中心自由基添加到氰胺化合物中,是芳香族多环胍衍生物的第一个自由基合成(参见方案)。底物的模块化组装使得支架的分子复杂性迅速增加,这些支架在药物化学中具有潜在的应用。
  • Tautomerism of quinazolin-4-ones with 2,3-annulated hydrogenated 1,3-diazaheterocycles. Synchronous and asynchronous double proton transfer in cyclic hydrogen-bonded associates
    作者:A. S. Morkovnik、L. N. Divaeva
    DOI:10.1007/s11172-009-0111-6
    日期:2009.5
    It was shown by quantum chemical methods and 1H NMR spectroscopy that in the series of prototropic tautomeric quinazolin-4-ones with hydrogenated 1,3-diazaheterocycles annulated at positions 2 and 3, namely, imidazole, pyrimidine, or [1,3]diazepine (compounds 1–3, respectively), the 1H-tautomeric form strongly predominates in the gas phase and in solutions regardless of the nature of these cycles. Tautomerization of tricycles 1–3 occurs via the intermolecular mechanism to form as intermediates hydrogen-bonded cyclodimers of these compounds or their cyclosolvates with proton-donor solvents. The key step of the reaction is the intraassociated concerted double proton transfer, which can proceed in nearly synchronous and asynchronous modes. In particular, double proton transfer in cyclodimers of quinazolinones 1–3 is asynchronous and proceeds with the formation of solvate-stabilized polar transition states, which are similar in structure to ionic intermediates of the nonconcerted double proton transfer.
    量子化学方法和 1H NMR 光谱显示,在原向同分异构喹唑啉-4-酮系列中,氢化的 1,3-二氮杂环在第 2 位和第 3 位环化,即咪唑、嘧啶或 [1,3]diazepine(分别为化合物 1-3),无论这些循环的性质如何,1H-同分异构形式在气相和溶液中都占主导地位。三环 1-3 的同分异构反应是通过分子间机理进行的,中间产物是这些化合物的氢键环二聚体或它们与质子供体溶剂的环溶剂化物。反应的关键步骤是联合体内部协同的双质子转移,它可以以近乎同步和异步的模式进行。特别是,喹唑啉酮环二聚体 1-3 中的双质子转移是异步的,并以形成溶胶稳定的极性转变态的方式进行,这种转变态的结构与非一致双质子转移的离子中间体相似。
查看更多

同类化合物

阿斯普尼辛B 阿斯普尼辛 D 阿斯普尼辛 苯佐莫文 新骏河毒素 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) TAK960抑制剂 PLK1抑制剂(RO3280) 8H-嘧啶并[4,5-b][1,4]二氮杂卓 8-甲基-5,9-二氢-6H-嘧啶并[4,5-b][1,4]重氮基庚英-6-酮 6H-嘧啶并[4,5-b][1,4]二氮杂卓 4-甲基-6,11-二氢-3H-嘧啶并[4,5-b][1,5]苯并二氮杂卓-2,5-二酮 2-氯-7,7-二氟-5-甲基-5,7,8,9-四氢-6H-嘧啶基[4,5-B][1,4]二氮杂-6-酮 2-氯-5-甲基-5,7,8,9-四氢-6H-嘧啶[4,5-B][1,4]二氮杂6-酮 1H-嘧啶并[4,5-b][1,4]二氮杂卓 4-amino-8-(1,3-benzodioxol-5-yl)-6-phenyl-8,9-dihydro-7H-pyrimido[4,5-b][1,4]diazepine 2-(2-Bromo-4-isopropyl-phenyl)-4-methyl-6-pentyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 2-chloro-8-(trifluoromethyl)-6H,11H-benzo[b]pyrimidino[5,4-f]-1,4-diazaperhydroepin-5-one 4,5,6,7-tetrahydro-2,4-diphenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione 4,5,6,7-tetrahydro-4-methyl-2-phenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-2-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide di-tert-butyl (1r,4r)-4-(4-(9-cyclohexyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxybenzamido)cyclohexyl phosphate 2-(2-Bromo-4-isopropyl-phenyl)-6-(1-ethyl-propyl)-4-methyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 7,8,9,10-tetrahydro-10-hydroxy-9-heptyl-[1,4]diazepino[1,2,3-g,h]purine 7,8,9,10-tetrahydro-10-hydroxy-9-methyl-9-propyl[1,4]diazepino[1,2,3-g,h]purine 6-cyclopentyl-9-[(3-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one 6-cyclopentyl-9-[(2-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one tert-butyl 8,10-dibromo-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate tert-butyl 8,10-dimethyl-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate 11-Diallylaminoacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 6-butyl-11-diallylaminoacetyl-2-phenyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 11-chloroacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 4-[(2-cyclopentyl-4,4,6-trimethyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]benzoic acid 4-[(2-cyclopentyl-6-methyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]-3-methoxy-N-(4-piperidyl)benzamide 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-N-(1-ethyl-4-piperidyl)-3-methoxy-benzamide 8-(4-chlorophenyl)-6-phenyl-9H-pyrimido[4,5-b][1,4]diazepin-4-ol 1-chloro-7-methoxy-8-(3-morpholin-4-yl-propoxy)-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cycloheptene 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-3-methoxy-N-methyl-benzamide (S)-tert-butyl (4-chloro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-7-yl)carbamate 3-methoxy-4-[[6-(2-methoxyethyl)-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl]amino]-N-(1-methyl-4-piperidyl)benzamide (9aS,9R)-4-chloro-N-(4-methylphenyl)-9a,10,11,12-tetrahydro-9H-pyrimido[4,5-b]dipyrrolo[1,2-d:2',1'-g][1,4]diazepin-9-amine